Shire gambit aimed at delaying generic Adderall XR
Seeking to protect its market for the hyperactivity drug Adderall XR, Shire Pharmaceuticals filed a Citizens Petition asking regulators to require any generic competitor to demonstrate its equal effectiveness from the patient's perspective. That kind of testing requirement would likely delay any approval of a copycat competitor. A group of generic drug makers, including Teva, have filed abbreviated new drug applications for generic Adderall XR. Adderall XR represents half of Shire's annual sales revenue.
- read this report from AFX for more
More stories about competitors sales and marketing Generics Regulators Shire Pharmaceuticals Adderall Teva
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage


